HARBIN, China, April 23 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it obtained approvals from the State Food and Drug Administration (SFDA) in China for the production of Geranium ointment and Musk liniment for pain relief.
Geranium ointment is used to cure chronic eczema, carbuncle, furuncle and small scalds. Musk liniment is used to relieve the pain from scathe, wound, rheumatism and arthrosis. It can be used to treat skin sores and blood clots. There are only one or two competitors supplying these products to the market. Management expects that the two new products will have a large market potential since many patients in China are suffering from these diseases, especially in rural areas. The Company estimates that the two products combined will contribute $0.8 million to revenues in 2009 and potentially much more in 2010.
"We are very pleased to receive SFDA approvals for these two drugs in a timely manner, which we believe will benefit an increasing number of patients in China as a result of the new health care system reforms," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We remain confident in our ability to identify drugs that have strong market potential that will enhance our overall portfolio."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its wholly-owned
subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company
("TDR"), Harbin Fir
|SOURCE China Sky One Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved